Abbott Labs completes $20 billion senior notes offering to fund Exact Sciences deal
Abbott Laboratories completed a $20 billion offering of senior notes on March 9, 2026, in seven fixed-rate and floating-rate series maturing between 2029 and 2066. The company said it will use the proceeds, together with cash on hand and/or additional borrowings, mainly to fund the consideration for its pending acquisition of Exact Sciences, repay certain Exact Sciences debt, and cover fees and general corporate purposes. The notes add $20 billion of debt to Abbott's balance sheet, and if the acquisition is not completed by the outside deadline, Abbott must redeem the notes at 101% of principal plus accrued interest.
Key points
- Total offering of $20 billion across eight note series, with the largest series being $3.75 billion each for the 5.500% notes due 2056 and 4.650% notes due 2036
- Notes were sold under a pricing agreement dated February 23, 2026, with Morgan Stanley, Barclays, BofA Securities and J.P. Morgan among the underwriters
- Proceeds are earmarked for the Exact Sciences acquisition under a merger agreement dated November 19, 2025
- If the acquisition is not consummated by five business days after the later of February 17, 2027 or any later agreed End Date, or Abbott notifies the trustee it will not pursue the deal, the notes must be redeemed at 101% of principal plus
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.